Anebulo Pharmaceuticals, Inc.
ANEB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $810 | $1,126 | $638 | $1,221 |
| G&A Expenses | $0 | $0 | $0 | $1,368 |
| SG&A Expenses | $1,450 | $1,205 | $1,254 | $1,368 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,260 | $2,331 | $1,892 | $2,588 |
| Operating Income | -$2,260 | -$2,331 | -$1,892 | -$2,588 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $102 | $186 | $216 | $125 |
| Pre-Tax Income | -$2,158 | -$2,145 | -$1,676 | -$2,463 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,158 | -$2,145 | -$1,676 | -$2,463 |
| % Margin | – | – | – | – |
| EPS | -0.05 | -0.052 | -0.041 | -0.09 |
| % Growth | 4.2% | -27.9% | 54.6% | – |
| EPS Diluted | -0.05 | -0.052 | -0.061 | -0.09 |
| Weighted Avg Shares Out | 41,085 | 41,085 | 27,415 | 27,415 |
| Weighted Avg Shares Out Dil | 41,085 | 41,085 | 27,415 | 27,415 |
| Supplemental Information | – | – | – | – |
| Interest Income | $110 | $123 | $102 | $7 |
| Interest Expense | $17 | $17 | $245 | $60 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2,141 | -$2,127 | -$1,431 | -$2,403 |
| % Margin | – | – | – | – |